.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Agilus Diagnostics has launched the automated Idylla system at its Goregaon laboratory in Mumbai. This advanced platform revolutionizes clinical workflows by delivering rapid cancer mutation testing in just 2.5 to 3 hours. Consequently, clinicians can now bypass conventional testing methods that typically take several days to process.
Furthermore, this technology allows oncologists to make timely, biomarker-driven treatment decisions during critical windows. Because of this speed, patients can begin targeted therapies without unnecessary delays.
The cartridge-based Idylla platform fully automates the testing process. Specifically, it integrates sample processing, nucleic acid extraction, amplification, and detection into a single workflow. Therefore, it minimizes manual intervention and reduces pre-analytical variability. This automation ensures highly accurate and reproducible results.
Additionally, the system detects critical genetic mutations across various cancer types. For instance, it identifies EGFR mutations, which frequently occur in lung cancer patients within Indian and Asian populations. It also screens for KRAS and NRAS mutations, which are crucial biomarkers in colorectal and pancreatic cancers. Moreover, it detects BRAF mutations found in melanoma and colorectal cancers.
Beyond these standard markers, the platform supports testing for emerging biomarkers. These include Microsatellite Instability (MSI) and IDH1/IDH2 mutations. Consequently, clinicians can better determine patient eligibility for advanced immunotherapies and targeted treatments.
Oncologists often face limited tissue samples in advanced cases. Therefore, the ability to obtain reliable genomic insights quickly is invaluable. The platform's high analytical performance helps optimize clinical outcomes when time is of the essence. As a result, India is taking a major step forward in expanding access to precision medicine.
Q1: What is the main advantage of the Idylla molecular diagnostics system?
The system delivers highly accurate genetic mutation results within 2.5 to 3 hours. Consequently, it is significantly faster than traditional molecular tests that require several days.
Q2: Which cancer biomarkers can this platform detect?
The platform identifies key mutations such as EGFR, KRAS, NRAS, and BRAF. Additionally, it supports testing for emerging markers like MSI and IDH1/IDH2.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Agilus Diagnostics has launched the cartridge-based Idylla molecular diagnostics system in Mumbai. The automated platform reduces cancer mutation testing times to 2.5–3 hours, enabling clinicians to identify key genetic biomarkers and initiate targeted therapies much faster than conventional methods.
3 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
